Saleem Jessani 1, Rasool Bux 1 and Tazeen H. Jafar 1,2. 1 Aga Khan University, Karachi, Pakistan 2 Duke-NUS Graduate Medical School, Singapore Socio-demographic.

Slides:

Advertisements

Similar presentations

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center.

Advertisements

JNC 8 Guidelines….

Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.

Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.

Factors associated with prediabetes in adult children of patients with premature coronary heart disease; the study of families of patients with premature.

CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.

NHANES III Prevalence of Hypertension* According to BMI

Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.

Association of 1,5-Anhydroglucitol with Diabetes and Microvascular

Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.

Change in prevalence of Chronic Kidney Disease in England over time: comparison of nationally representative cross-sectional surveys from 2003 to 2010.

LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]

A Dr. Sunita Dodani Assistant professor, Family Medicine The Aga Khan University Karachi, Pakistan Dr. David MacLean Professor, Simon Fraser University,

Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.

Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid- lowering Treatment to Prevent Heart.

1 ATRIAL FIBRILLATION AT BASELINE AND DURING FOLLOW-UP in The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial November 9, 2003.

Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.

1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.

Clinical Characteristic of Patients with Uncontrolled, Potentially Under-treated and Apparent Treatment Resistant Hypertension: NHANES 1988  Brent.

Duality of interests S.Yusuf has received fees for lecturing and research grants from Cadilla Pharma, as well as from 6 other pharma companies that produce.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

Diabetes National Diabetes Control Programme

Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients Dr. Mya Thandar.

High level of low density lipoprotein cholesterol in adult children of patients with premature coronary heart disease: relation to own and parental characteristics.

To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.

Association between Systolic Blood Pressure and Congestive Heart Failure Complication among Hypertensive and Diabetic Hypertensive Patients Mrs. Sutheera.

HDL LowLess than 40 mg/dL High60 mg/dL and above LDL OptimalLess than 100 mg/dL Near Optimal mg/dL Borderline High mg/dL High mg/dL.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

Risk factor profile for chronic non-communicable diseases: Results of a community-based study in Kerala, India K.R. Thankappan, Bela Shah*, Prashant Mathur*,

Lesotho STEPS Survey 2012 Fact Sheet John Nkonyana Director Disease Control.

Age Adjusted Prevalence of Hypertension* Among Adults by Education in NYC, 2004 Data from: New York City Department of Health and Mental Hygiene, EpiQuery.

Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:

1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Stroke epidemic in Pakistan Mohammad Wasay, MD, FRCP, FAAN Aga Khan University.

Dr. Nadira Mehriban. INTRODUCTION Diabetic retinopathy (DR) is one of the major micro vascular complications of diabetes and most significant cause of.

Professor Tazeen H Jafar Duke-National University of Singapore & Aga Khan University, Karachi, Pakistan Chronic Kidney Disease- Integration into the NCD.

○ South Asians (SAs) have high rates of CHD which are not entirely explained by traditional CVD risk factors. ○ The association of a family history of.

The short term effects of metabolic syndrome and its components on all-cause-cause mortality-the Taipei Elderly Health Examination Cohort Wen-Liang Liu.

Date of download: 6/25/2016 From: Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2013;159(4):

Figure 1.1 Prevalence of CKD by stage among NHANES participants,

Blood Pressure and Lipid Trials: Rationale, Importance and Design

－ Higher SBP visit-to-visit variability (SBV) has been associated

From ESH 2016 | LB 3: Davide Agnoletti, MD

Baseline characteristics and effectiveness results

Elevated Circulating Levels of Inflammatory Markers in

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

HDL cholesterol and cardiovascular risk Epidemiological evidence

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Dr. Ranomal Kotak, Dr. Rozina Mistry and Intisaar Ahmed

The percentage of subjects with de novo development of renal function impairment (GFR

Progress and Promise in RAAS Blockade

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Mean BP from initial visit to four years

Determinants of new onset diabetes among hypertensive patients randomised in the ASCOT-BPLA Trial Dr Ajay K Gupta International Centre for Circulatory.

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Table of Contents Why Do We Treat Hypertension? Recommendation 5

The prevalence of Recurrent Stroke and TIA and the related factors

Baseline Characteristics of the Subjects*

PROSPER: trial design

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Saleem Jessani 1, Rasool Bux 1 and Tazeen H. Jafar 1,2. 1 Aga Khan University, Karachi, Pakistan 2 Duke-NUS Graduate Medical School, Singapore Socio-demographic CKD IN PAKISTAN Socio-demographic and Clinical Determinants

INTRODUCTION CKD is increasing being recognized as a global public health problem. CKD is associated with substantial morbidity and mortality. It affects about 5–7% of the world population and is more common in developing countries However, information on the prevalence and determinants of CKD and its management in the developing countries especially the South Asian region is lacking.

OBJECTIVES To determine the prevalence of CKD To determine socio-demographic and clinical factors associated with CKD To explore the existing management of patients with CKD with regards to  BP control  Use of antihypertensive medications

METHODS Study design - Study design - Population based cross-sectional study Study participants - Study participants adults from the COBRA StudyPredictors  Socio-demographic: Age, Sex, Education, Tobacco use & Physical activity  Clinical: BMI, Hypertension, Diabetes, SBP, DBP, h/o CAD, h/o Stroke, Fasting Glucose, Triglycerides, Total Cholesterol, LDL, HDL,

METHODS (CONT…) Study outcome  CKD was defined as eGFR < 60 mL/min/1.73 m 2 (reduced eGFR) or Urine ACR ≥ 30 mg/g (albuminuria) based on the spot urine sample eGFR was estimated using the CKD-EPI Pakistan equation (0.686 × CKD-EPI (Jessani et al. AJKD 2014.)

Rationale for using CKD-EPI Pakistan P 30 Accuracy = 68.0%P 30 Accuracy = 76.1%

Rationale for using CKD-EPI Pakistan P 30 Accuracy = 76.1%P 30 Accuracy = 81.6% Correction Factor: × CKD-EPI 1.059

Prevalence of CKD and Reduced eGFR Age groups / Disease Prevalence, % (95% CI) Overall (n=2873)Men (N= 1374)Women (N=1499) Overall (n=2873) CKD Reduced eGFR 12.5 (11.3 – 13.8) 5.3 (4.5 – 6.2) 11.6 (9.9 – 13.4) 5.2 (4.1 – 6.5) 13.3 (11.7 – 15.2) 5.5 (4.4 – 6.7) 40 – 49 yrs (n=1429) CKD Reduced eGFR 5.9 (4.7 – 7.2) 1.3 (0.7 – 2.0) 6.2 (4.5 – 8.3) 1.6 (0.8 – 2.9) 5.6 (4.1 – 7.5) 0.9 (0.4 – 1.9) 50 – 59 yrs (n=755) CKD Reduced eGFR 14.2 (11.8 – 16.9) 5.3 (3.8 – 7.1) 11.5 (8.4 – 15.3) 4.9 (3.0 – 7.7) 16.6 (13.1 – 20.7) 5.6 (3.6 – 8.4) ≥ 60 yrs (n=689) CKD Reduced eGFR 24.4 (21.2 – 27.8) 13.8 (11.3 – 16.6) 22.6 (18.2 – 27.5) 12.7 (9.3 – 16.7) 26.1 (21. 6 – 30.9) 14.8 (11.3 – 19.0)

Socio-demographic and Clinical Characteristics of individuals with and without CKD CharacteristicsTotal (n=2873) CKD Status Negative 2514 (87.4) Positive 359 (12.5) Age in years, mean ± SD51.5 ± ± ± 12.3* Women, n (%)1499 (52.2)1299 (51.7)200 (55.7) Primary or higher Edu, n (%)1881 (65.5)1682 (66.9) 199 (55.4)* Current Tobacco users, n (%)1113 (38.7) 980 (39.0) 133 (37.0) Phy. Activity, METs < 840, n (%)1725 (60.0)1473 (58.6)252 (70.2)* Hypertension, n (%)1267 (44.9)1013 (41.0)254 (72.2)* Diabetes Mellitus, n (%)615 (21.4)465 (18.5)150 (41.8)* History of CHD, n (%)246 (8.6)203 (8.1)43 (12.0)* History of stroke, n (%)88 (3.1)59 (2.3)29 (8.1)* Body mass index, mean ± SD25.8 ± ± 5.1 Systolic BP, mean ± SD137 ± ± ± 27* Diastolic BP, mean ± SD86 ±1385 ±1291 ± 15* Fasting glucose, mean ± SD115.8 ± ± ± 69.3* S. Cholesterol, mean ± SD188.0 ± ± ± 48.2* LDL, mean ± SD115.6 ± ± ± 37.1 HDL, mean ± SD40.2 ± ± ± 12.2 Triglycerides, mean ± SD159.3 ± ± ± 103.8*

Multivariable Regression Models for CKD Characteristics Model 1 Adj. OR (95% CI) Model 2 Adj. OR (95% CI) Age in years / For each 1 year increase1.06 (1.05 – 1.07) Physical Activity < 840 METs vs. ≥ 840 METs 1.35 (1.04 – 1.75) - Hypertension Hypertensive vs. Non-hypertensive NA 1.90 (1.40 – 2.57) Diabetes mellitus Diabetic vs. Non-diabetic NA 1.69 (1.18 – 2.43) History of stroke Positive vs. Negative NA 1.73 (1.03 – 2.92) Systolic BP / each 1 mmHg increase NA (1.008 – 1.020) Fasting glucose / each 1 mg/dL increase NA (1.001 – 1.007) Triglycerides / each 1 mg/dL increase NA (1.00 – 1.003) Model1 = Socio-demographic determinants; Model 2 = Socio-demographic & clinical determinants

BP Control and Use of Antihypertensive medications among CKD Patients Characteristics Overall Urine ACR, mg/g, n (%, 95% CIs) <30.0≥ 30.0 n=267N=56N=211 BP ≤ 140/90 mm Hg, n (%) (95% CI) 51 (19.1) (14.6 – 24.3) 13 (23.2) (13.0 – 36.4) 38 (18.0) (13.1 – 23.9) BP ≤ 130/80 mm Hg, n (%) (95% CI) 17 (6.4) (3.8 – 10.0) 6 (10.7) (4.0 – 21.9) 11 (5.2) (2.6 – 9.1) Use of Antihypertensive meds, n (%) (95% CI) 130 (48.7) (42.6 – 54.9) 33 (58.9) (45.0 – 71.9) 97 (46.0) (39.1 – 52.9)

Use of Antihypertensive Medications by Class of Drugs among CKD Patients Antihypertensive medications Overall Urine ACR, mg/g, n (%, 95% CIs) <30.0≥ 30.0 n=267N=56N=211 ACEI/ARB 26 (9.7) (6.5 – 13.9) 7 (12.5) (5.2 – 24.1) 19 (9.0) (5.5 – 13.7) Beta blockers 43 (16.1) (11.9 – 21.1) 9 (16.1) (7.6 – 28.3) 34 (16.1) (11.4 – 21.8) Calcium channel blockers 18 (6.7) (4.0 – 10.4) 4 (7.1) (2.0 – 17.3) 14 (6.6) (3.7 – 10.9) Diuretics 3 (1.1) (0.2 – 3.2) 2 (3.6) (0.4 – 12.3) 1 (0.5) (0.0 – 2.6) Alpa-2 agonist /alpha blockers 4 (1.5) (0.4 – 3.8) 1 (1.8) (0.0 – 9.6) 3 (1.4) (0.3 – 4.1) Combinations† 36 (13.5) (9.6 – 18.2) 10 (17.9) (8.9 – 30.4) 26 (12.3) ( 8.2 – 17.5) †Combinations are based on various groups of above mentioned anti-hypertensive drugs.

CONCLUSIONS CKD is common among Pakistani adults. BP control among these patients is grossly sub-optimal. The socio-demographic and clinical factors associated with CKD highlight the need for integration of CKD prevention efforts along with other non-communicable diseases in Pakistan.

Thank you